Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single‐institution, retrospective case series

Vaccaro, Mario; Santarpia, M.; Calapai, Gioacchino; Mannucci, Carmen; Borgia, Francesco; Altavilla, Giuseppe; Cannavò, Serafinella Patrizia

doi:10.1111/bjd.14806

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to cytotoxic drugs, these “biologic” therapies are better tolerated, even if they share many cutaneous adverse events with traditional drugs. 2 – 5 Nevertheless, an increasing number of oncologic patients experience multi-organ toxicities that reflect the effects of the drug on targets not relevant to tumor response and the impact of toxic metabolites. 6 More significantly, many of these toxicities are associated with the impact of the drug on its target, thus representing a potentially reliable clinical biomarker to detect best responders among patients.…”

Section: Discussionmentioning

confidence: 99%

Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment

Borgia

Saitta

Vaccaro

et al. 2017

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC). It is associated with a significant risk of skin toxicity, which nevertheless represents a clinical marker of good response to treatment. Hand-and-foot skin reaction, alopecia, mucositis, xerosis, skin discoloration, and nail involvement occur frequently in course of therapy. More rarely, sorafenib can target hair follicles. We report the case of a patient who developed painful inflamed nodular-cystic lesions in both pubic and axillary regions in course of treatment with sorafenib. Because of the limited therapeutic options, the patient underwent photodynamic therapy (PDT), a topical treatment which combines a photosensitizing drug applied on lesional skin and a source of light, and had no systemic side effects. At the end of the treatment period, the patient experienced progressive clinical improvement, with relief of the symptoms. PDT may be helpful to limit suffering in patients affected by recalcitrant skin toxicity of the pilosebaceous unit who are not candidates for, or not responsive to, standard therapies.

show abstract